Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer

ClinicalTrials.gov ID: NCT01044745

Public ClinicalTrials.gov record NCT01044745. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 7, 2026, 8:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Rituximab For Prevention Of Acute Graft-Versus-Host Disease (GVHD) After Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (HCT)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This phase II trial is studying how well rituximab works in preventing acute graft-versus-host disease (GVHD) in patients undergoing a donor stem cell transplant for hematologic cancer. Giving chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving a monoclonal antibody, rituximab, together with anti-thymocyte globulin, tacrolimus, and mycophenolate mofetil before and after the transplant may stop this from happening

Study identification

NCT ID: NCT01044745
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: University of Nebraska; Other
Enrollment: 20 participants

Conditions and interventions

Conditions

Interventions

rituximab Drug
mycophenolate mofetil Drug
tacrolimus Drug
anti-thymocyte globulin Drug
allogeneic hematopoietic stem cell transplantation Procedure
laboratory biomarker analysis Other
graft versus host disease prophylaxis/therapy Biological
cyclophosphamide Drug
fludarabine phosphate Drug
busulfan Drug
total-body irradiation Radiation
graft-versus-tumor induction therapy Biological
immunosuppressive therapy Biological

Drug · Procedure · Other + 2 more

Eligibility (public fields only)

Age range: 19 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 9, 2009
Primary completion: Dec 18, 2012
Completion: Oct 9, 2017
Last update posted: Sep 5, 2023

2009 – 2017

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
University of Nebraska Medical Center	Omaha	Nebraska	68198	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01044745, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 5, 2023 · Synced Sep 7, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01044745 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →